Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 539

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 539
---
 Note 8. Commitments and Contingencies
The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.

See Note 3 for discussion of research and development funding commitments and developmental and regulatory milestone payment obligations under the CAR-T License and the Vaccine License. See Note 7 for discussion on funding commitments on the Note.

<div align='center'>F-84</div>

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO FINANCIAL STATEMENTSDECEMBER 31, 2023 AND 2022

#### Note 9. Subsequent Events
The Company has completed an evaluation of all subsequent events through May 13, 2024, the date the financial statements are available to be issued to ensure that these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements.

On January 5, 2024, the Company funded an additional advance under the Note of $0.7 million, which resulted in a total outstanding principal balance of $1.5 million.

On January 5, 2024, January 8, 2024, and January 22, 2024, the Company borrowed additional amounts from Valetudo totaling $0.8 million.

On February 28, 2024, the Company amended and restated the Note with Iris (the “Amended Note”). The Amended Note increased the principal amount from $1.5 million to $2.5 million.

On March 6, 2024, the Company borrowed an additional $0.3 million from Prophase.

On March 9, 2024, the Company entered into a third amendment to the Business Combination Agreement extending the outside date to July 31, 2024.

On April 2, 2024, the Company funded an additional advance under the Amended Note of $0.3 million.

On May 1, 2024, the Company borrowed an additional $0.1 million from Prophase.

On May 7, 2024, the Company funded an additional advance under the Amended Note of $0.03 million.

On May 13, 2024, the Company borrowed an additional $0.2 million from Prophase, and funded an additional advance under the